+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now
pharmaceutical reports

Pharmaceutical CDMO Services on the Rise

13 February 2020
Pharma
pharmaceutical reports

The pharmaceutical market is one of today’s fastest-growing industries, which is why the professionals from Visiongain have made it their business to help companies and stakeholders stay up to date. One sector experiencing significant growth is that of contract development and manufacturing organization (CDMO) services.

Here you’ll find all you need to know about this fast-growing sector of the pharmaceutical industry and how investors can be poised to generate big returns in the years ahead.

What Exactly Do CDMOs Do?

Before jumping into some of the benefits of investing in CDMO services, it’s important to have a clear idea of their function in the pharmaceutical industry. Basically, CDMOs provide companies in the pharmaceutical industry with some of the key components necessary to bring a drug or treatment to the market. They’re responsible for the research, manufacturing, and development services necessary for companies to produce specialized drugs and other pharmaceutical products.

Why Do CDMOs Have Such a Significant Market Segment?

CDMOs make up a substantial segment of the pharmaceutical market these days for several reasons, the first being that they help ensure drug manufacturers that all of the products they produce are of the highest possible quality. By contract manufacturing, pharma companies can ensure that the proper quality standards, performance measures, and safety regulations are followed during the manufacturing of their products. This in turn not only provides added oversight into the manufacturing process but also helps manufacturers save on research and development costs.

Trends & Opportunities in the Global CDMO Market

One of the leading opportunities in the global CDMO market is the need for such services in various regions due to existing supply-demand deficits. Additionally, with the expanded development of generic drugs, more pharmaceutical companies are looking to minimize production costs while simultaneously taking advantage of such deficits, making working with CDMOs ever more popular. Some of the key regions that are experiencing significant growth include Europe, due to a more practical and businesslike approach to contract production, and the Asia-Pacific region due to the larger populations in areas such as India and China.

Let us provide the pharmaceutical reports & insights you need to excel!

If you want to keep up with all of the current trends and changes in the pharmaceutical industry, the team from Visiongain has the information you need. All of our reports are based on comprehensive primary and secondary sources and are compiled by knowledgeable industry experts. With more than 1,500 reports available spanning over 18 market verticals, Visiongain has developed a reputation in the market research industry for providing the essential information necessary for businesses to experience long-term success.

To learn more about what we do, contact us online today or call +44 (0) 20 7549 9987.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read